Skip to main content
Clinical Trials/NCT03180398
NCT03180398
Terminated
Not Applicable

Pilot Study of Using Multi-parametric Magnetic Resonance Imaging for Organ Delineation and Tumor Response Assessment of Prostate Cancer Patients Being Treated With Radiation Therapy

Henry Ford Health System1 site in 1 country9 target enrollmentOctober 4, 2017
ConditionsProstate Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Henry Ford Health System
Enrollment
9
Locations
1
Primary Endpoint
Detection of Imaging Biomarkers to Localize the Intraprostatic Lesions and Predict Radiation Treatment Response
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

This is a pilot study of implement multi-parametric MR imaging for organ delineation and tumor response assessment of prostate cancer patients being treated with radiation therapy.

Detailed Description

The study aims to generate intraprostatic lesions maps based on imaging, perform the treatment planning to compute the highest feasible simultaneous boosting dose to intraprostatic lesion and characterize longitudinal changes in imaging characteristics.

Registry
clinicaltrials.gov
Start Date
October 4, 2017
End Date
February 15, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Stephen Brown

Director, Radiobiology Research Laboratories

Henry Ford Health System

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed prostate adenocarcinoma

Exclusion Criteria

  • Patients with metal fragments or implanted devices such as pacemakers and aneurysm clips are not eligible for the study considering

Outcomes

Primary Outcomes

Detection of Imaging Biomarkers to Localize the Intraprostatic Lesions and Predict Radiation Treatment Response

Time Frame: 2 years

Identify the radiomics features selected from multimodal MRI to distinguish the dominant lesions from the normal tissues within the prostate. Track the changes of these features with longitudinal MRI scans to identify its correlation with the local control.

Tumor Response

Time Frame: 2 years

Tumor response as measured by an increase in PSA.

Study Sites (1)

Loading locations...

Similar Trials